TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?

Core Insights - Tempus AI and Doximity are prominent players in the Medical Information Systems industry, with Tempus focusing on precision medicine through AI and Doximity serving as a medical network for U.S. physicians [1][2] Company Overview Tempus AI - Tempus specializes in precision medicine, aggregating multimodal data from clinical care and laboratory testing to provide AI-enabled solutions [1] - The Diagnostics segment is a key growth driver, with revenues from profiling assays supporting therapy selection and disease monitoring, achieving a 111.5% year-over-year growth in 2025 [5][9] - The Data and Applications segment also saw significant growth, with a 30.9% year-over-year increase in sales [6] - Tempus is developing AI-driven clinical applications, including TIME and Next, to enhance patient matching and care pathway intelligence [7][10] Doximity - Doximity has a strong presence, reaching over 80% of U.S. physicians, with its AI tools experiencing over fivefold growth year over year [2][11] - The company reported a 10% revenue growth in fiscal Q3 2026, supported by user engagement, surpassing 3 million registered members [11][12] - Doximity's AI products are rapidly adopted, with over 300,000 prescribers using these tools, enhancing engagement and positioning for future revenue opportunities [12][13] Market Context - The global healthcare information systems market is projected to reach nearly $1,773.33 billion by 2034, attracting investor interest in this sector [3] - Over the past year, Tempus and Doximity's shares have declined by 10.2% and 58.1%, respectively [4] Financial Performance Tempus AI - The Zacks Consensus Estimate for Tempus indicates a loss per share of 34 cents for 2026, reflecting a 44.3% year-over-year improvement [14] - Tempus trades at a forward price-to-sales (P/S) ratio of 4.50X, which is lower than its median [16] Doximity - The Zacks Consensus Estimate for Doximity's fiscal 2026 earnings per share is projected at $1.54, indicating an 8.5% year-over-year growth [14] - Doximity's P/S ratio stands at 6.35X, also below its median [16] Investment Outlook - Tempus is positioned as a compelling player in diagnostics and AI-enabled healthcare innovation, despite uncertainties regarding the sustainability of its growth rates [17][18] - Doximity continues to show solid growth and user engagement, with a favorable outlook for unlocking additional revenue streams through product innovation [19]